title: The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia.
abstract: The effect of chlormadinone acetate (CMA), a synthetic steroidal antiandrogen, on spontaneous benign prostatic hyperplasia (BPH) in dogs was investigated. Male beagle dogs (5-8 years old) were divided into four experimental group. Group 1 consisted of untreated controls. Groups 2 and 3 received CMA 0.03 and 0.1 mg/kg/day, p.o., respectively, for 6 months. In group 1, glandular hyperplasia of the prostate was clearly detected. The glandular epithelial cells showed uniformly intense nuclear staining for androgen receptor (AR). AR was also localized in the nuclei of the fibro-muscular stromal cells. In groups 2 and 3, CMA produced marked atrophy of the glandular epithelium. The interacinar fibro-muscular stroma was prominent. The nuclear staining for AR in both epithelial and stromal cells was remarkably decreased. In addition, a histopathological study showed that CMA medication for 6 months exerted no effect on the testes and adrenal glands or on immunoreactive positive cells to LH- and ACTH-antibody (pituitary LH- and ACTH-cells). Therefore, it is concluded that CMA (0.03 and 0.1 mg/kg) causes regression of spontaneous canine BPH without any histopathological effects on the testes, adrenal glands or pituitary LH- and ACTH-cells.
authors.affiliation: Safety Research Department, Teikoku Hormone Mfg. Co., Ltd., 1604 Shimosakunobe, Takatsu-ku, Kawasaki-city, Kanagawa 213-8522, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Murakoshi
authors.forename: R
authors.initials: R
authors.lastname: Ikeda
authors.forename: N
authors.initials: N
authors.lastname: Fukui
mesh_terms: D000311:Adrenal Glands / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D000324:Adrenocorticotropic Hormone / Q000032:analysis; D000726:Androgen Antagonists / Q000009:adverse effects*; D000818:Animals; D002715:Chlormadinone Acetate / Q000009:adverse effects*; D004285:Dogs; D019084:Fluorescent Antibody Technique, Indirect; D007150:Immunohistochemistry; D007986:Luteinizing Hormone / Q000032:analysis; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010902:Pituitary Gland / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D011467:Prostate / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011944:Receptors, Androgen / Q000032:analysis; D013737:Testis / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology
chemical_list: D000726:Androgen Antagonists; D011944:Receptors, Androgen; D002715:Chlormadinone Acetate; D000324:Adrenocorticotropic Hormone; D007986:Luteinizing Hormone